SE9500478D0 - New pharmaceutical formulation and process - Google Patents

New pharmaceutical formulation and process

Info

Publication number
SE9500478D0
SE9500478D0 SE9500478A SE9500478A SE9500478D0 SE 9500478 D0 SE9500478 D0 SE 9500478D0 SE 9500478 A SE9500478 A SE 9500478A SE 9500478 A SE9500478 A SE 9500478A SE 9500478 D0 SE9500478 D0 SE 9500478D0
Authority
SE
Sweden
Prior art keywords
alkaline reacting
core material
enteric coating
dosage form
water soluble
Prior art date
Application number
SE9500478A
Other languages
English (en)
Swedish (sv)
Inventor
Per Johan Gunnar Lundberg
Kurt Ingemar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20397154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9500478(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9500478A priority Critical patent/SE9500478D0/xx
Publication of SE9500478D0 publication Critical patent/SE9500478D0/xx
Priority to US08/612,951 priority patent/US6013281A/en
Priority to RU96120189/14A priority patent/RU2170090C2/ru
Priority to PCT/SE1996/000161 priority patent/WO1996024338A1/en
Priority to EP96902579A priority patent/EP0752851B1/en
Priority to BR9605121A priority patent/BR9605121A/pt
Priority to EP01125523A priority patent/EP1174136A3/en
Priority to KR1019960705620A priority patent/KR100405586B1/ko
Priority to AT96902579T priority patent/ATE218327T1/de
Priority to AU46839/96A priority patent/AU695774C/en
Priority to CZ19962918A priority patent/CZ291720B6/cs
Priority to CA002186037A priority patent/CA2186037C/en
Priority to HU9603112A priority patent/HUP9603112A3/hu
Priority to PT96902579T priority patent/PT752851E/pt
Priority to JP52420996A priority patent/JP3881377B2/ja
Priority to DE69621523T priority patent/DE69621523T2/de
Priority to MX9604497A priority patent/MX9604497A/es
Priority to EE9600148A priority patent/EE03379B1/xx
Priority to CNB961900903A priority patent/CN1182841C/zh
Priority to ES96902579T priority patent/ES2179175T3/es
Priority to DK96902579T priority patent/DK0752851T3/da
Priority to ZA9601078A priority patent/ZA961078B/xx
Priority to SI9630509T priority patent/SI0752851T1/xx
Priority to UA96114336A priority patent/UA44890C2/uk
Priority to SK1261-96A priority patent/SK281202B6/sk
Priority to NZ301424A priority patent/NZ301424A/en
Priority to TR96/00785T priority patent/TR199600785T1/xx
Priority to PL96316685A priority patent/PL184433B1/pl
Priority to IS4359A priority patent/IS1884B/is
Priority to NO19964271A priority patent/NO315925B1/no
Priority to FI964028A priority patent/FI119141B/fi
Priority to HK98109233A priority patent/HK1008302A1/xx
Priority to US09/413,521 priority patent/US20020012676A1/en
Priority to US10/023,968 priority patent/US20020086029A1/en
Priority to US10/235,392 priority patent/US20030113375A1/en
Priority to US10/693,317 priority patent/US20040234594A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9500478A 1995-02-09 1995-02-09 New pharmaceutical formulation and process SE9500478D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9500478A SE9500478D0 (sv) 1995-02-09 1995-02-09 New pharmaceutical formulation and process
TR96/00785T TR199600785T1 (tr) 1995-02-09 1996-02-09 Yeni ispenciyari formülasyonlar ve metodu.
PL96316685A PL184433B1 (pl) 1995-02-09 1996-02-09 Sposób wytwarzania preparatu farmaceutycznego
DE69621523T DE69621523T2 (de) 1995-02-09 1996-02-09 Verfahren zur herstellung einer pharmazeutischen formulierung
CNB961900903A CN1182841C (zh) 1995-02-09 1996-02-09 新的药物制剂及其制备方法
PCT/SE1996/000161 WO1996024338A1 (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process
EP96902579A EP0752851B1 (en) 1995-02-09 1996-02-09 Process for preparing a pharmaceutical formulation
BR9605121A BR9605121A (pt) 1995-02-09 1996-02-09 Formulação de dosagem farmecêutica oral processo para a preparação de uma formulação de dosagem farmacêutica oral revestida entericamente processo para inibir a secreção ácida gástrica em mamíferos e no ser human e uso de uma formulação de dosagem farmacêutica oral
EP01125523A EP1174136A3 (en) 1995-02-09 1996-02-09 Oral pharmaceutical dosage form containing a proton pump inhibitor
KR1019960705620A KR100405586B1 (ko) 1995-02-09 1996-02-09 신규한제약제형및이의제조방법
AT96902579T ATE218327T1 (de) 1995-02-09 1996-02-09 Verfahren zur herstellung einer pharmazeutischen formulierung
AU46839/96A AU695774C (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process
CZ19962918A CZ291720B6 (cs) 1995-02-09 1996-02-09 Způsob přípravy orálního farmaceutického prostředku
CA002186037A CA2186037C (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process
HU9603112A HUP9603112A3 (en) 1995-02-09 1996-02-09 New pharmaceutical formulation and process for its production
PT96902579T PT752851E (pt) 1995-02-09 1996-02-09 Processo para a preparacao de uma formulacao farmaceutica
JP52420996A JP3881377B2 (ja) 1995-02-09 1996-02-09 新規な製剤および方法
US08/612,951 US6013281A (en) 1995-02-09 1996-02-09 Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
MX9604497A MX9604497A (es) 1995-02-09 1996-02-09 Nueva formulacion farmaceutica y procedimiento.
EE9600148A EE03379B1 (et) 1995-02-09 1996-02-09 Enterokattega peroraalse ravimvormi valmistamise protsess
RU96120189/14A RU2170090C2 (ru) 1995-02-09 1996-02-09 Способ получения фармацевтической лекарственной формы, способ ингибирования секреции кислоты в желудке у млекопитающих и человека
ES96902579T ES2179175T3 (es) 1995-02-09 1996-02-09 Proceso para preparar una formulacion farmaceutica.
DK96902579T DK0752851T3 (da) 1995-02-09 1996-02-09 Fremgangsmåde til fremstilling af et farmaceutisk præparat
ZA9601078A ZA961078B (en) 1995-02-09 1996-02-09 New pharamceutical formulation and process.
SI9630509T SI0752851T1 (en) 1995-02-09 1996-02-09 Process for preparing a pharmaceutical formulation
UA96114336A UA44890C2 (uk) 1995-02-09 1996-02-09 Спосіб одержання фармацевтичної лікарської форми для перорального введення
SK1261-96A SK281202B6 (sk) 1995-02-09 1996-02-09 Spôsob prípravy orálneho farmaceutického prípravku
NZ301424A NZ301424A (en) 1995-02-09 1996-02-09 Manufacture of coated tablet with two functionally different layers one being a core material containing a proton pump inhibitor
IS4359A IS1884B (is) 1995-02-09 1996-09-17 Aðferð til að framleiða lyf á skammtaformi til inntöku um munn sem inniheldur prótónupumpuhemil
FI964028A FI119141B (fi) 1995-02-09 1996-10-08 Menetelmä farmaseuttisen formulaation valmistamiseksi
NO19964271A NO315925B1 (no) 1995-02-09 1996-10-08 Fremgangsmåte for fremstilling av en oral farmasöytisk doseringsform, og anvendelse derav
HK98109233A HK1008302A1 (en) 1995-02-09 1998-07-17 Process for preparing a pharmaceutical formulation
US09/413,521 US20020012676A1 (en) 1995-02-09 1999-10-06 New pharmaceutical formulation and process
US10/023,968 US20020086029A1 (en) 1995-02-09 2001-12-18 Pharmaceutical formulation and process
US10/235,392 US20030113375A1 (en) 1995-02-09 2002-09-04 Pharmaceutical formulation and process
US10/693,317 US20040234594A1 (en) 1995-02-09 2003-10-23 Pharmaceutical formulation and process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500478A SE9500478D0 (sv) 1995-02-09 1995-02-09 New pharmaceutical formulation and process

Publications (1)

Publication Number Publication Date
SE9500478D0 true SE9500478D0 (sv) 1995-02-09

Family

ID=20397154

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9500478A SE9500478D0 (sv) 1995-02-09 1995-02-09 New pharmaceutical formulation and process

Country Status (29)

Country Link
US (5) US6013281A (xx)
EP (2) EP1174136A3 (xx)
JP (1) JP3881377B2 (xx)
KR (1) KR100405586B1 (xx)
CN (1) CN1182841C (xx)
AT (1) ATE218327T1 (xx)
BR (1) BR9605121A (xx)
CA (1) CA2186037C (xx)
CZ (1) CZ291720B6 (xx)
DE (1) DE69621523T2 (xx)
DK (1) DK0752851T3 (xx)
EE (1) EE03379B1 (xx)
ES (1) ES2179175T3 (xx)
FI (1) FI119141B (xx)
HK (1) HK1008302A1 (xx)
HU (1) HUP9603112A3 (xx)
IS (1) IS1884B (xx)
MX (1) MX9604497A (xx)
NO (1) NO315925B1 (xx)
NZ (1) NZ301424A (xx)
PL (1) PL184433B1 (xx)
PT (1) PT752851E (xx)
RU (1) RU2170090C2 (xx)
SE (1) SE9500478D0 (xx)
SK (1) SK281202B6 (xx)
TR (1) TR199600785T1 (xx)
UA (1) UA44890C2 (xx)
WO (1) WO1996024338A1 (xx)
ZA (1) ZA961078B (xx)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
NZ337592A (en) * 1997-03-13 2001-01-26 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations
JP2001524131A (ja) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク 安定な経口医薬品剤形
US6143743A (en) 1997-07-03 2000-11-07 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
ATE321538T1 (de) 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60237087D1 (de) * 2001-06-01 2010-09-02 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
JP2005500307A (ja) * 2001-06-21 2005-01-06 アンドルックス ファーマスーティカルズ インコーポレーテッド プラバスタチンを含む安定な徐放性薬剤組成物
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
CN1596100A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 可食用组合物及含可食用外壳的制剂
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
KR100592511B1 (ko) * 2002-12-30 2006-07-03 안경섭 벤즈이미다졸 유도체 또는 약리학적으로 허용되는 이의염을 활성물질로 하는 안정성이 강화된 방출제어형 제제및 그 제조방법
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID
EP1602362B1 (en) * 2003-03-12 2016-09-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
CA2523218A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005044240A2 (en) * 2003-10-31 2005-05-19 Dexcel, Ltd. Stable lansoprazole formulation
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
KR100581967B1 (ko) * 2003-12-18 2006-05-22 한국유나이티드제약 주식회사 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
AU2005257977A1 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
CN100364989C (zh) * 2004-09-30 2008-01-30 江苏豪森药业股份有限公司 拉唑类衍生物及其盐和用途
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
KR100570446B1 (ko) * 2005-02-14 2006-04-12 지엘팜텍 주식회사 산 불안정성 약리활성물질 함유 장용성 경구용 제제 및 이의 제조방법
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
GB0514926D0 (en) * 2005-07-20 2005-08-24 Huntleigh Technology Plc Bed assembly
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2007099433A2 (en) * 2006-02-28 2007-09-07 Wockhardt Ltd Delayed release dosage form of pantoprazole or salt thereof
WO2007115305A2 (en) 2006-04-04 2007-10-11 Cogentus Pharmaceuticals, Inc. Oral dosage forms including an antiplatelet agent and an acid inhibitor
DE102006017896A1 (de) † 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
DE102008045339A1 (de) * 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
MX2012000057A (es) * 2009-06-25 2012-06-01 Pozen Inc Metodo para tratar a un paciente con necesidad de terapia de aspirina.
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
JP5691142B2 (ja) * 2009-07-17 2015-04-01 ニプロ株式会社 ベンズイミダゾール系注射剤
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CN102085188B (zh) * 2011-01-14 2013-01-02 寿光富康制药有限公司 一种兰索拉唑肠溶微丸的制备方法
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013141827A1 (en) 2012-03-21 2013-09-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric coated solid pharmaceutical compositions for proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
ZA861026B (en) * 1985-02-13 1986-09-24 Ciba Geigy Ag Pesticidal compositions
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
PL166209B1 (pl) * 1990-06-20 1995-04-28 Astra Ab Sposób wytwarzania nowych pochodnych benzimidazolu PL
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
EE03378B1 (et) * 1994-07-08 2001-04-16 Astra Aktiebolag Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm
PT1078628E (pt) * 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
PT752851E (pt) 2002-11-29
IS4359A (is) 1996-09-17
SK126196A3 (en) 1997-10-08
EP0752851B1 (en) 2002-06-05
BR9605121A (pt) 1997-10-14
EP1174136A2 (en) 2002-01-23
NO315925B1 (no) 2003-11-17
FI964028A (fi) 1996-10-08
TR199600785T1 (tr) 1997-08-21
ATE218327T1 (de) 2002-06-15
NO964271L (no) 1996-10-08
ES2179175T3 (es) 2003-01-16
HUP9603112A3 (en) 2001-12-28
NZ301424A (en) 1998-07-28
AU4683996A (en) 1996-08-27
CN1182841C (zh) 2005-01-05
RU2170090C2 (ru) 2001-07-10
CA2186037A1 (en) 1996-08-15
KR100405586B1 (ko) 2004-05-31
US20020086029A1 (en) 2002-07-04
US20020012676A1 (en) 2002-01-31
EP0752851A1 (en) 1997-01-15
MX9604497A (es) 1997-11-29
UA44890C2 (uk) 2002-03-15
FI119141B (fi) 2008-08-15
PL316685A1 (en) 1997-02-03
US6013281A (en) 2000-01-11
ZA961078B (en) 1997-08-11
JP3881377B2 (ja) 2007-02-14
WO1996024338A1 (en) 1996-08-15
CN1146720A (zh) 1997-04-02
JPH09511768A (ja) 1997-11-25
NO964271D0 (no) 1996-10-08
HUP9603112A2 (en) 1997-08-28
AU695774B2 (en) 1998-08-20
DE69621523T2 (de) 2003-01-30
FI964028A0 (fi) 1996-10-08
IS1884B (is) 2003-08-15
DE69621523D1 (de) 2002-07-11
DK0752851T3 (da) 2002-09-16
HK1008302A1 (en) 1999-05-07
EE03379B1 (et) 2001-04-16
PL184433B1 (pl) 2002-10-31
US20030113375A1 (en) 2003-06-19
EE9600148A (et) 1997-04-15
SK281202B6 (sk) 2001-01-18
EP1174136A3 (en) 2003-04-23
CA2186037C (en) 2002-04-16
US20040234594A1 (en) 2004-11-25
CZ291720B6 (cs) 2003-05-14
CZ291896A3 (en) 1997-07-16

Similar Documents

Publication Publication Date Title
SE9500478D0 (sv) New pharmaceutical formulation and process
DE69628444D1 (de) Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung
NZ505127A (en) Oral pharmaceutical extended release dosage form of proton pump inhibitor
RU96107040A (ru) Многоединичный фармацевтический препарат, содержащий ингибитор протонного насоса
SI1037634T1 (sl) Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol)
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
HU9301577D0 (en) Method for manufacturing peroral medical preparative
HU9600572D0 (en) Medicament for inhibiting gastric acid secretion, multiple unit tablated dosage form
FI973733A (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
ES2006457T3 (es) Nueva preparacion farmaceutica para uso oral.
SE9700885D0 (sv) New pharmaceutical formulation
ATE442852T1 (de) Trimetazidine enthaltendes arzneimittel mit verzögerter wirkstoffabgabe und verfahren zur herstellung
NO975660D0 (no) Anvendelse av benzimidazoler for fremstilling av et medikament for behandling av levkemi
FI932552A0 (fi) Foerfarande foer framstaellning av en fast enhet doseringsform foer reglerad utloesningen
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης
FR2820600B1 (fr) Procede pour la fabrication d'un film electroluminescent et application d'un tel film
MY102850A (en) New pharmaceutical preparation for oral use.
HUP9902933A2 (hu) Verapamil alkalmazása angina kezelésére szolgáló gyógyszer előállítására
TH19832A (th) สูตรผสมทางเภสัชกรรมชนิดใหม่ที่ประกอบรวมด้วยเกลือแมกนีเซียมของออเมพราโซลที่มีรูปแบบทางกายภาพชนิดใหม่และวิธีสำหรับการผลิตเกลือนี้